Products
Magellan manufactures mesenchymal stem cell products for the treatment of osteoarthritis.
Autologous stem cell treatments
Magellan’s autologous products use each patient’s own stem cells to treat their osteoarthritis.
A patient’s cells are harvested, expanded and undergo quality control to ensure the stem cells are viable, free of any contamination and are truly stem cells based on the international stem cell classifications.
More than 1500 people have been treated in these autologous stem cell trials for osteoarthritis, with the results published in scientific journals.
Donor stem cell treatment
Magellan has developed MAG200, an off-the-shelf mesenchymal stem cell treatment for osteoarthritis.
MAG200, an allogenic or donor product, has undergone Phase I/IIa trials and a Phase III trial is planned to commence in late 2025.
The early trials indicated the product is safe and has efficacy, also indicating that stem cells are “immune evasive”, i.e. don’t trigger an immune response.
Magellan believes MAG200 has the potential to defer the need for expensive joint replacement surgery for many osteoarthritis sufferers.
Stem cell trials
Magellan and our research collaboration partners at Melbourne Stem Cell Centre Research have undertaken or contributed to both autologous (patients’ own) and allogeneic (donor) stem cell research and trials.
Magellan’s MAG200 allogeneic (donor) product has undergone Phase I/IIa trials, with the results published in Osteoarthritis and Cartilage Open.
Links to Magellan’s published research are available on the Research page.
Magellan Stem Cells product MAG200 to date
Pre-clinical research
Phase I & II for Clinical Safety and primary efficacy
Phase III for Clinical Efficacy Trial – beginning in 2025
Our product MAG200 has successfully completed Phase I/II of a clinical trials on the use of allogeneic (donor) off-the-shelf stem cell therapy for OA. The pivotal Phase III trial is planned to commence in 2025.
Magellan Stem cells has secured a laboratory in southeast Melbourne and commenced construction of a good manufacturing practice laboratory. This was completed in 2023. Magellan has secured a GMP licence from the TGA.
